Alnylam Pharmaceuticals

Entry	Author	Date	Location
What Are the Hottest Targets in Biotech Today?	Luke Timmerman	04/23/12	National
AIDS Drugs Were the Start. Let’s See More FDA Accelerated Approvals	Luke Timmerman	03/12/12	National
Reinventing Biotech: Meet Corey Goodman, Kevin Starr & More April 3	Luke Timmerman	02/23/12	Seattle
Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans	Luke Timmerman	01/19/12	Boston
Join Kevin Starr, Corey Goodman, Carl Weissman & More in Seattle April 3	Luke Timmerman	01/19/12	Seattle
Biology 101	John Maraganore	01/18/12	Boston
Alnylam, Aveo, Biogen, & More Boston Life Sciences Newsmakers	Erin Kutz	01/06/12	Boston
Alnylam Gets First Hint of Effectiveness for RNAi Cholesterol-Lowering Drug	Luke Timmerman	01/04/12	Boston
Vertex, Ariad, Alnylam, & More Boston-Area Life Sciences Newsmakers	Erin Kutz	12/16/11	Boston
Alnylam Racing to Prove RNAi Works, For a Disease You’ve Never Heard Of	Luke Timmerman	12/13/11	Boston
Langer Nabs Cash From Rock Stars, Verastem Seeks $50M IPO, Alnylam Snags RNAi Collab, & More Boston-Area Life Sciences News	Erin Kutz	11/04/11	Boston
Alnylam and Glaxo Partner on RNAi for Vaccine Production	Arlene Weintraub	11/01/11	Boston
Celgene Pays Agios $20M, Lycera Adds Cambridge CEO, Getinge Buys Atrium Medical, & More Boston-Area Life Sciences News	Erin Kutz	10/07/11	Boston
Light Sciences Stumbles, Cardiac Dimensions Gets EU OK, Immune Design Pockets $11M, & More Seattle-Area Life Sciences News	Luke Timmerman	10/06/11	Seattle
Tweetchat on RNA Interference Upstages iPhone (Not Really, but It Was Still Fun)	Luke Timmerman	10/05/11	National
Join Us at 1 pm Eastern/10 am Pacific for RNAi “Tweetchat” with Alnylam’s John Maraganore	Luke Timmerman	10/04/11	National
UW Scores $40M for Biofuels, Cocrystal’s Fight Against HepC, The Women’s Biotech Network, & More Seattle-Area Life Sciences News	Luke Timmerman	09/29/11	Seattle
Join Us for a Live ‘Tweetchat’ on the Future of RNAi, With Guest John Maraganore of Alnylam	Luke Timmerman	09/28/11	National
Stirring the Pot Once in a While Doesn’t Hurt, and It Could Help Biotech Break its Malaise	Luke Timmerman	09/19/11	National
Merck Shuts Down RNAi Research Center in SF, Cutting 50 Jobs	Luke Timmerman	07/29/11	San Francisco
ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S.	Luke Timmerman	06/07/11	National
Vertex Gets FDA OK, Alnylam Plans For ASCO, Biogen Drug Advances in Europe, & More Boston-Area Life Sciences News	Erin Kutz	05/27/11	Boston
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired	Luke Timmerman	05/23/11	National
Will Biotech Ever Again Captivate the Public Imagination, Like Facebook or LinkedIn?	Luke Timmerman	05/16/11	National
Alnylam Inks Deal with Precision NanoSystems	Ryan McBride	04/19/11	Boston
The New Tech Bubble, Biotech Vs. Big Pharma, and More Thoughts from Boston BD Conference	Gregory T. Huang	04/14/11	Boston
Westphal Leaving Glaxo, Cubist Settles Patent Litigation with Teva, BSX Buys S.I., & More Boston-Area Life Sciences News	Erin Kutz	04/08/11	Boston
Omeros Flunks Pivotal Trials, Dendreon’s Shareholder Hubbub, AVI Biopharma Nabs $30M, & More Seattle-Area Life Sciences News	Luke Timmerman	04/07/11	Seattle
Alnylam Responds to Tekmira Suit	Luke Timmerman	04/06/11	Boston
Christoph Westphal Leaving GSK’s SR One to Focus on Longwood Founders Fund	Gregory T. Huang	04/04/11	Boston
Page 1 of 7	next page »

Entry

Author

Date

Location

What Are the Hottest Targets in Biotech Today?

Luke Timmerman

04/23/12

National

AIDS Drugs Were the Start. Let’s See More FDA Accelerated Approvals

Luke Timmerman

03/12/12

National